StockData

Genelux vs Alaunos Therapeutics

GNLX and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GNLX and TCRT compare

Genelux is the larger company, worth 21 times as much as Alaunos Therapeutics ($90.5M against $4.2M).

Genelux scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGNLXTCRT
Size and price
Market cap$90.5M$4.2M
Share price$2.00$1.66
Change, 1 year−62.4%−44.1%
Change, 5 years–−99.2%
Beta (5Y)0.73−2.45
Employees–1
StockData Score
Total score5 (better)4
Valuation score00
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S–1406×
P/B5.6× (better)6.5×
FCF yield−31.7%–
Growth
Revenue growth (TTM)–−50.0%
Profitability
Operating margin–−135267%
Net margin–−133667%
Return on equity−178% (better)−186%
Return on invested capital–−489%
Financial health
Debt / equity0.000.00
Current ratio2.39 (better)0.77
Altman Z-score−14.83 (better)−861.74
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−20.8%–
Shareholder yield−20.8%0.00% (better)
Ownership
Held by institutions21.7%3.6%
Held by insiders7.7%69.8%
Insider net buying, 12 months−$341K–
Short interest, % of float10.9%24.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.